No Data
Direct coverage of the Star medical instruments industry collective Earnings Conference: Multiple companies are laying out AI medical Business, and key segments in innovation fields may accelerate the development of domestic production.
① Attending companies believe that tariff policies will bring some cost pressures and market challenges to enterprises, but at the same time, it has accelerated the localization process in relevant fields; ② Some attending companies disclosed the latest developments in their Business during the earnings briefing and the planning for related lines by 2025.
Australian and Chinese Endoscopy: Report for the first quarter of 2025
2025 First Quarter Report
Aohua Endoscopy (688212.SH): has repurchased a cumulative 1.02% of the company's shares.
On April 17, Gelonghui reported that Aohua Endoscopy (688212.SH) announced that as of April 17, 2025, the company has repurchased a total of 1.3704 million shares through the centralized bidding trading system of the Shanghai Exchange, accounting for 1.02% of the company's total equity. The highest repurchase price was 41.99 yuan per share, the lowest was 37.50 yuan per share, and the total funds paid amount to 55.242 million yuan (excluding stamp duty, transaction commissions, and other trading fees).
Australasia Endoscope (688212.SH): Net loss of 28.7915 million yuan in the first quarter.
Gelonghui, April 17丨 Auhua Endoscopy (688212.SH) announced its first quarter report for 2025, with a revenue of 0.124 billion yuan, a year-on-year decrease of 26.92%; Net income attributable to shareholders of the listed company was -28.7915 million yuan; EPS was 0.21 yuan.
Why Shanghai Aohua Photoelectricity Endoscope's (SHSE:688212) Shaky Earnings Are Just The Beginning Of Its Problems
There's Been No Shortage Of Growth Recently For Shanghai Aohua Photoelectricity Endoscope's (SHSE:688212) Returns On Capital
